Product
Mini-hyper-CVD
1 clinical trial
2 indications
Indication
Relapsed/RefractoryIndication
B-cell ALLClinical trial
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabStatus: Not yet recruiting, Estimated PCD: 2028-12-31